PharmiWeb.com - Global Pharma News & Resources
PharmiWeb Today Story
Baxter Expands Pharmaceuticals Portfolio with New Injectable Products in the U.S.
  • Five new launches reinforce Baxter’s focus on differentiated products and enhance the company’s Pharmaceuticals portfolio in critical therapeutic areas

  • Products feature ready-to-use formulations to help support patient safety and offer added convenience for healthcare professionals

DEERFIELD, Ill. - 2024-04-11

Baxter International Inc. (NYSE:BAX), a global leader in injectables, anesthesia and drug compounding, announced the continued expansion of its Pharmaceuticals portfolio with five injectable product launches in the U.S. 

“These launches demonstrate Baxter’s focus on differentiated products that address unmet patient needs in key therapeutic areas, including anti-infective and anti-hypotensive medications,” said Alok Sonig, executive vice president and group president, Pharmaceuticals, at Baxter. “We are proud to offer important new options for our customers and look forward to continuing to bring new innovations to the market.” 

Product launches within Baxter’s Pharmaceuticals portfolio in the U.S. include the following. For all products, please see full Indications, Important Risk Information and links to full Prescribing Information below.

  • Norepinephrine Bitartrate in 5% Dextrose Injection in a new 16 mg/250 mL strength, which is indicated to raise blood pressure in adult patients with severe, acute hypotension. Baxter offers the first and only FDA-approved ready-to-use Norepinephrine in Dextrose, and now provides Norepinephrine in 4 mg/250 mL, 8 mg/250 mL and 16 mg/250 mL strengths.
  • Vasopressin in 0.9% Sodium Chloride Injection, the fir…
Read More...
Baxter Expands Pharmaceuticals Portfolio with New Injectable Products in the U.S.

Articles